Rep. Gilbert Ray Cisneros, Jr. Buys Artivion, Inc. (NYSE:AORT) Stock

Key Points

• Rep. Gilbert Ray Cisneros Jr. purchased $1,001–$15,000 of Artivion stock on August 20, 2026, according to a congressional disclosure. He also recently bought shares of Quanta Services, Eaton, Wheaton Precious Metals, Walmart and Goldman Sachs while selling several other holdings.
• Artivion shares opened at $25.13, with a $1.23 billion market capitalization, after the stock gained 1.9%. The company reported quarterly revenue of $125.76 million and earnings of $0.13 per share, exceeding analysts’ revenue expectations.
• Analysts maintain a generally positive outlook, with seven Buy ratings and one Sell rating and a consensus price target of $44.83. However, company insiders have sold 90,460 shares worth about $2.56 million over the past three months.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Artivion, Inc. (NYSE:AORT). In a filing disclosed on September 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in Artivion stock on August 20th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of DoorDash NASDAQ: DASH on 8/28/2026.
• Purchased $15,001 - $50,000 in shares of Quanta Services NYSE: PWR on 8/27/2026.
• Purchased $15,001 - $50,000 in shares of Eaton NYSE: ETN on 8/27/2026.
• Sold $15,001 - $50,000 in shares of NIKE NYSE: NKE on 8/27/2026.
• Sold $1,001 - $15,000 in shares of Phreesia NYSE: PHR on 8/26/2026.
• Purchased $1,001 - $15,000 in shares of Wheaton Precious Metals NYSE: WPM on 8/26/2026.
• Purchased $1,001 - $15,000 in shares of Walmart NASDAQ: WMT on 8/26/2026.
• Purchased $1,001 - $15,000 in shares of The Goldman Sachs Group NYSE: GS on 8/26/2026.
• Sold $15,001 - $50,000 in shares of Lamar Advertising NASDAQ: LAMR on 8/25/2026.
• Sold $1,001 - $15,000 in shares of Phreesia NYSE: PHR on 8/25/2026.

Artivion Stock Up 1.9%

Artivion stock opened at $25.13 on Friday. The stock has a market capitalization of $1.23 billion, a price-to-earnings ratio of -358.92 and a beta of 1.25. The company has a current ratio of 3.47, a quick ratio of 2.51 and a debt-to-equity ratio of 0.82. Artivion, Inc. has a twelve month low of $19.16 and a twelve month high of $48.25. The stock has a 50 day moving average of $26.27 and a two-hundred day moving average of $28.78.

Artivion (NYSE:AORT - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter. The business had revenue of $125.76 million for the quarter, compared to the consensus estimate of $119.99 million. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. As a group, research analysts expect that Artivion, Inc. will post 0.45 earnings per share for the current year.

Institutional Trading of Artivion

A number of institutional investors and hedge funds have recently bought and sold shares of AORT. Caitong International Asset Management Co. Ltd purchased a new stake in Artivion during the 3rd quarter worth $27,000. Rockefeller Capital Management L.P. increased its holdings in Artivion by 150.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company's stock valued at $30,000 after buying an additional 399 shares during the last quarter. Larson Financial Group LLC increased its holdings in shares of Artivion by 148.5% in the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company's stock valued at $43,000 after acquiring an additional 563 shares during the last quarter. Smartleaf Asset Management LLC raised its position in shares of Artivion by 47.7% during the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company's stock valued at $52,000 after acquiring an additional 538 shares in the last quarter. Finally, Kemnay Advisory Services Inc. bought a new position in shares of Artivion in the 4th quarter worth about $79,000. Institutional investors and hedge funds own 86.37% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings downgraded shares of Artivion from a "sell (d+)" rating to a "sell (d-)" rating in a research report on Tuesday, August 11th. Stifel Nicolaus set a $45.00 price objective on shares of Artivion in a research note on Monday, June 1st. Canaccord Genuity Group increased their price objective on shares of Artivion from $39.00 to $40.00 and gave the stock a "buy" rating in a report on Tuesday, August 18th. Citigroup reissued a "market outperform" rating on shares of Artivion in a research report on Tuesday, July 21st. Finally, Needham & Company LLC restated a "buy" rating and issued a $44.00 target price on shares of Artivion in a report on Monday, July 20th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Artivion currently has a consensus rating of "Moderate Buy" and a consensus price target of $44.83.

Insider Buying and Selling at Artivion

In other Artivion news, SVP Andrew M. Green sold 11,480 shares of the firm's stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $24.97, for a total value of $286,655.60. Following the sale, the senior vice president owned 40,160 shares in the company, valued at approximately $1,002,795.20. This trade represents a 22.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO James P. Mackin sold 70,000 shares of the stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $28.95, for a total value of $2,026,500.00. Following the completion of the transaction, the chief executive officer directly owned 877,275 shares of the company's stock, valued at $25,397,111.25. This trade represents a 7.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 90,460 shares of company stock worth $2,557,366. 6.30% of the stock is owned by insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Artivion

Artivion, Inc NYSE: AORT is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.